X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1448) 1448
Book Review (230) 230
Publication (105) 105
Book Chapter (5) 5
Magazine Article (5) 5
Newsletter (5) 5
Conference Proceeding (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1341) 1341
female (1025) 1025
humans (946) 946
raloxifene hydrochloride - pharmacology (894) 894
raloxifene (733) 733
animals (625) 625
selective estrogen receptor modulators - pharmacology (546) 546
postmenopausal women (442) 442
estrogen (341) 341
rats (340) 340
estradiol - pharmacology (331) 331
raloxifene hydrochloride - therapeutic use (331) 331
pharmacology & pharmacy (310) 310
middle aged (294) 294
estrogen antagonists - pharmacology (290) 290
tamoxifen (290) 290
tamoxifen - pharmacology (284) 284
endocrinology & metabolism (254) 254
osteoporosis (253) 253
breast-cancer (224) 224
selective estrogen receptor modulators - therapeutic use (222) 222
raloxifene hydrochloride (220) 220
aged (214) 214
ovariectomy (213) 213
hormone replacement therapy (174) 174
piperidines - pharmacology (172) 172
male (170) 170
mice (159) 159
bone density - drug effects (158) 158
obstetrics & gynecology (144) 144
receptors, estrogen - metabolism (144) 144
rats, sprague-dawley (142) 142
estradiol (141) 141
oncology (139) 139
raloxifene hydrochloride - administration & dosage (137) 137
dose-response relationship, drug (136) 136
estrogens - pharmacology (134) 134
breast cancer (128) 128
abridged index medicus (125) 125
bone-mineral density (124) 124
postmenopause (123) 123
breast neoplasms - prevention & control (120) 120
risk (117) 117
osteoporosis, postmenopausal - drug therapy (115) 115
tamoxifen - therapeutic use (114) 114
breast neoplasms - drug therapy (109) 109
women (109) 109
menopause (107) 107
prevention (106) 106
biochemistry & molecular biology (105) 105
estradiol - analogs & derivatives (105) 105
analysis (104) 104
cells, cultured (102) 102
receptors, estrogen - drug effects (101) 101
adult (99) 99
ovariectomized rats (98) 98
expression (96) 96
in-vitro (96) 96
rats, wistar (95) 95
cell line, tumor (93) 93
estrogen replacement therapy (93) 93
bone density conservation agents - pharmacology (91) 91
raloxifene hydrochloride - adverse effects (91) 91
uterus - drug effects (88) 88
raloxifene hydrochloride - chemistry (86) 86
double-blind method (85) 85
cancer (84) 84
estrogen antagonists - therapeutic use (84) 84
healthy postmenopausal women (82) 82
osteoporosis - drug therapy (80) 80
bone and bones - drug effects (79) 79
phenols (79) 79
tamoxifen - analogs & derivatives (78) 78
estrogen-receptor modulators (75) 75
osteoporosis, postmenopausal - prevention & control (75) 75
selective estrogen receptor modulators - administration & dosage (74) 74
time factors (73) 73
randomized-trial (72) 72
health aspects (71) 71
serm (71) 71
tumor cells, cultured (70) 70
chemistry, medicinal (69) 69
medicine & public health (69) 69
treatment outcome (69) 69
drug therapy (68) 68
risk factors (68) 68
therapy (67) 67
bone density conservation agents - therapeutic use (66) 66
research (66) 66
breast neoplasms - metabolism (64) 64
selective estrogen receptor modulators - adverse effects (64) 64
cell proliferation - drug effects (63) 63
estrogen receptors (63) 63
trial (63) 63
serms (62) 62
serum-cholesterol (61) 61
antiestrogens (60) 60
cell biology (60) 60
disease models, animal (60) 60
estrogen receptor alpha - metabolism (60) 60
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1400) 1400
Japanese (27) 27
Chinese (9) 9
French (7) 7
Spanish (5) 5
Polish (4) 4
German (3) 3
Dutch (2) 2
Hungarian (2) 2
Italian (2) 2
Croatian (1) 1
Czech (1) 1
Finnish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chemical Research in Toxicology, ISSN 0893-228X, 09/2008, Volume 21, Issue 9, pp. 1814 - 1822
In vitro covalent binding assessments of drugs have been useful in providing retrospective insights into the association between drug metabolism and a... 
ACYL GLUCURONIDES | CHEMISTRY, MEDICINAL | PROTEIN | RAT | REACTIVE METABOLITES | TIENILIC ACID | HEPATIC-NECROSIS | BIOACTIVATION | IDENTIFICATION | CHEMISTRY, MULTIDISCIPLINARY | MASS-SPECTROMETRY | TOXICOLOGY | HUMAN URINE | Buspirone - chemistry | Raloxifene Hydrochloride - pharmacology | Thiazoles - metabolism | Acetaminophen - metabolism | Humans | Microsomes, Liver - metabolism | Indomethacin - metabolism | Simvastatin - pharmacology | Diclofenac - chemistry | Thiazines - metabolism | Propranolol - pharmacology | Toxicity Tests - methods | Binding Sites | Simvastatin - metabolism | Microsomes, Liver - chemistry | Indomethacin - pharmacology | Paroxetine - metabolism | Raloxifene Hydrochloride - metabolism | Triazoles - metabolism | Ticrynafen - metabolism | Paroxetine - pharmacology | Diclofenac - metabolism | Paroxetine - chemistry | Diphenhydramine - pharmacology | Diclofenac - pharmacology | Triazoles - chemistry | Buspirone - metabolism | Ticrynafen - pharmacology | Structure-Activity Relationship | Buspirone - pharmacology | Hepatocytes - metabolism | Dose-Response Relationship, Drug | Carbamazepine - chemistry | Diphenhydramine - metabolism | Acetaminophen - pharmacology | Microsomes, Liver - drug effects | Propranolol - metabolism | Carbamazepine - metabolism | Thiazines - pharmacology | Molecular Structure | Drug Evaluation, Preclinical | Hepatocytes - drug effects | Carbamazepine - pharmacology | Simvastatin - chemistry | Acetaminophen - chemistry | Ticrynafen - chemistry | Propranolol - chemistry | Diphenhydramine - chemistry | Thiazines - chemistry | Triazoles - pharmacology | Indomethacin - chemistry | Thiazoles - chemistry | Thiazoles - pharmacology | Raloxifene Hydrochloride - chemistry | Index Medicus
Journal Article
Journal Article
Cancer Prevention Research, ISSN 1940-6207, 06/2010, Volume 3, Issue 6, pp. 696 - 706
The selective estrogen-receptor modulator (SERM) tamoxifen became the first U. S. Food and Drug Administration (FDA)-approved agent for reducing breast cancer... 
WOMEN | RISK-FACTORS | ONCOLOGY | ESTROGEN | FOLLOW-UP | OUTCOMES | MUTATIONS | NSABP | Uterus - pathology | Raloxifene Hydrochloride - adverse effects | Raloxifene Hydrochloride - pharmacology | Adenocarcinoma - pathology | Raloxifene Hydrochloride - therapeutic use | Cataract - chemically induced | Follow-Up Studies | Thromboembolism - chemically induced | Fractures, Spontaneous - epidemiology | Estrogens | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Endometrial Neoplasms - chemically induced | Selective Estrogen Receptor Modulators - adverse effects | Risk | Cataract - epidemiology | Thromboembolism - epidemiology | Drug Utilization | Incidence | Selective Estrogen Receptor Modulators - therapeutic use | Aged, 80 and over | Adult | Female | Osteoporosis, Postmenopausal - prevention & control | Breast Neoplasms - epidemiology | Myocardial Ischemia - epidemiology | Neoplasms, Hormone-Dependent - prevention & control | Double-Blind Method | Neoplasm Invasiveness | Myocardial Ischemia - prevention & control | Fractures, Spontaneous - etiology | Endometrial Neoplasms - epidemiology | Neoplasms, Hormone-Dependent - epidemiology | Breast Neoplasms - prevention & control | Adenocarcinoma - prevention & control | Fractures, Spontaneous - prevention & control | Breast Neoplasms - pathology | Neoplasms, Hormone-Dependent - pathology | Tamoxifen - therapeutic use | Tamoxifen - pharmacology | Aged | Tamoxifen - adverse effects | Adenocarcinoma - epidemiology | Selective Estrogen Receptor Modulators - pharmacology | Index Medicus
Journal Article
Fertility and Sterility, ISSN 0015-0282, 2009, Volume 92, Issue 3, pp. 1045 - 1052
Objective To evaluate the efficacy of the tissue-selective estrogen complex, bazedoxifene/conjugated estrogens (BZA/CE), for postmenopausal osteoporosis... 
Internal Medicine | Obstetrics and Gynecology | bone mineral density | tissue-selective estrogen complex | conjugated estrogens | osteoporosis | Bazedoxifene | EQUINE ESTROGEN | BONE-MINERAL DENSITY | CLINICAL-TRIAL | PLUS PROGESTIN | RALOXIFENE | HYSTERECTOMY | MEDROXYPROGESTERONE ACETATE | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | VERTEBRAL FRACTURE RISK | INITIATIVE RANDOMIZED-TRIAL | RECEPTOR MODULATOR | Collagen Type I - blood | Osteoporosis, Postmenopausal - epidemiology | Estrogens, Conjugated (USP) - pharmacology | Peptides - blood | Raloxifene Hydrochloride - pharmacology | Estrogens - pharmacology | Raloxifene Hydrochloride - therapeutic use | Humans | Middle Aged | Estrogens - therapeutic use | Dose-Response Relationship, Drug | Osteocalcin - blood | Selective Estrogen Receptor Modulators - therapeutic use | Adult | Female | Indoles - pharmacology | Osteoporosis, Postmenopausal - prevention & control | Double-Blind Method | Lumbar Vertebrae - diagnostic imaging | Risk Factors | Treatment Outcome | Lumbar Vertebrae - drug effects | Absorptiometry, Photon | Hip Joint - drug effects | Hip Joint - diagnostic imaging | Estrogens, Conjugated (USP) - therapeutic use | Bone Density - drug effects | Osteoporosis, Postmenopausal - blood | Indoles - therapeutic use | Aged | Selective Estrogen Receptor Modulators - pharmacology | Prevention | Benzoic acid | Osteoporosis | Medical colleges | Estrogen | Phenols | Postmenopausal women | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Science, ISSN 0036-8075, 3/2002, Volume 295, Issue 5564, pp. 2465 - 2468
Selective estrogen receptor modulators (SERMs) mimic estrogen action in certain tissues while opposing it in others. The therapeutic effectiveness of SERMs... 
Neuroscience | Transfection | RNA | Genes | Cell lines | Small interfering RNA | Phenols | Reports | Breast cancer | Selective estrogen receptor modulators | Endometrial neoplasms | HUMAN ESTROGEN-RECEPTOR | ACTIVATION | COACTIVATOR | ANTIESTROGEN | GENE | PROMOTER-CONTEXT | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION | C-MYC | 4-HYDROXYTAMOXIFEN | CANCER | Raloxifene Hydrochloride - pharmacology | Receptors, Estrogen - metabolism | Histone Acetyltransferases | Humans | Endometrial Neoplasms - metabolism | Endometrium - drug effects | Insulin-Like Growth Factor I - genetics | Genes, myc | Breast - metabolism | Breast Neoplasms - metabolism | DNA-Binding Proteins - metabolism | Endometrial Neoplasms - genetics | Female | Transcription, Genetic | Tumor Cells, Cultured | Estradiol - pharmacology | Repressor Proteins - metabolism | Endometrium - metabolism | Tamoxifen - metabolism | Promoter Regions, Genetic | Response Elements | Gene Silencing | Histone Deacetylases - metabolism | Transcription Factors - genetics | Organ Specificity | Selective Estrogen Receptor Modulators - metabolism | Gene Expression Regulation - drug effects | Transcription Factors - metabolism | Raloxifene Hydrochloride - metabolism | Breast Neoplasms - genetics | Receptors, Estrogen - chemistry | Cell Cycle | Breast - drug effects | Tamoxifen - pharmacology | Nuclear Receptor Coactivator 1 | Selective Estrogen Receptor Modulators - pharmacology | Raloxifene | Tamoxifen | Drug therapy | Health aspects | Tissue | Molecules | Estrogen | SRC-1 protein | raloxifene | Index Medicus
Journal Article
Journal Article
Osteoporosis International, ISSN 0937-941X, 4/2012, Volume 23, Issue 4, pp. 1235 - 1243
We determined whether suppression of sclerostin levels by estrogen treatment was mediated by anti-resorptive effect. Raloxifene, but not bisphosphonates,... 
Medicine & Public Health | Orthopedics | Gynecology | Rheumatology | Estrogen | Sclerostin | Raloxifene | Bone turnover | Bisphosphonates | Endocrinology | TURNOVER | BIOCHEMICAL MARKERS | STRENGTH | OSTEOPOROSIS | SKELETON | DELETION | BONE-FORMATION | DISEASE | ENDOCRINOLOGY & METABOLISM | SOST | LIGAND | Raloxifene Hydrochloride - pharmacology | Raloxifene Hydrochloride - therapeutic use | Humans | Middle Aged | Bone Morphogenetic Proteins - blood | Osteocalcin - blood | Selective Estrogen Receptor Modulators - therapeutic use | Bone Morphogenetic Proteins - drug effects | Diphosphonates - therapeutic use | Female | Retrospective Studies | Alkaline Phosphatase - blood | Drug Administration Schedule | Bone Density Conservation Agents - therapeutic use | Selective Estrogen Receptor Modulators - administration & dosage | Diphosphonates - administration & dosage | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Genetic Markers - drug effects | Bone Density - drug effects | Osteoporosis, Postmenopausal - blood | Raloxifene Hydrochloride - administration & dosage | Osteoporosis, Postmenopausal - physiopathology | Aged | Selective Estrogen Receptor Modulators - pharmacology | Diphosphonates - pharmacology | Cellular proteins | Osteoporosis | Physiological aspects | Postmenopausal women | Dosage and administration | Research | Drug therapy | Health aspects | Bones | Metabolism | Menopause | Index Medicus | Alkaline phosphatase | Osteocalcin | Estrogens | Estrogen receptors | SOST protein | Post-menopause
Journal Article
Journal Article